|
1) 上條敦子, 木村健二郎. 尿中肝臓型 fatty acid binding protein(L-FABP)の意義. Annual Review腎臓 2001. 東京: 中外医学社; 2001. p. 53
|
|
|
|
|
2) Kamijo A, Kimura K, Sugaya T, et al. Urinary fatty acid binding protein as a new clinical marker for the progression of chronic renal disease. J Lab Clin Med. 2004; 143: 23-30
|
|
|
|
|
3) Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid binding protein as a marker for monitoring chronic kidney disease: A Multi-Center Trial. J Lab Clin Med. 2005; 145: 125-33
|
|
|
|
|
|
4) Kamijo A, Sugaya T, Hikawa A, Y, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006: 284(1-2): 175-82
|
|
|
|
|
|
5) Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care. 2005; 28: 2728-32
|
|
|
|
|
|
6) Nakamura T, Sugaya T, Node K, et al. Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis. 2006; 47: 439-44
|
|
|
|
|
|
7) Portilla D, Dent C, Sugaya T, et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2008; 73: 465-72
|
|
|
|
|
|
8) Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008; 7: 489-503
|
|
|
|
|
|
9) Wolfrum C, Borrmann CM, Borchers T, et al. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha - and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci U S A. 2001; 98: 2323-8
|
|
|
|
|
|
10) Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004; 165: 1243-55
|
|
|
|
|
|
11) Yamamoto T, Noiri E, Ono Y, et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol. 2007; 18: 2894-902
|
|
|
|
|
|
12) Kamijo-Ikemori A, Sugaya T, Sekizuka A, et al. Amelioration of diabetic tubulointerstitial damage in liver type fatty acid binding protein transgenic mice. Nephrol Dial Transplant. 2008; in press
|
|
|
|
|
|
13) Kamijo-Ikemori A, Sugaya T, Obama A, et al. Liver type fatty acid binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am J Pathol. 2006; 169: 1107-17
|
|
|
|
|
|
14) Negishi K, Noiri E, Maeda R, et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int. 2008; 73: 1374-84
|
|
|
|
|
|
15) Tanaka T, Noiri E, Yamamoto T, et al. Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury. Nephron Exp Nephrol. 2008; 108: e19-26
|
|
|
|
|
|
16) Nakamura T, Sugaya T, Kawagoe Y, et al. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol. 2006; 65: 1-6
|
|
|
|
|
|
17) Nakamura T, Sugaya T, Kawagoe Y, et al. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci. 2005; 330: 161-5
|
|
|
|
|
|
18) Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev. 2006; 22: 385-9
|
|
|
|
|
|
19) Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol. 2006; 26: 82-6
|
|
|
|
|